DOR BioPharma Reports Positive New Survival Findings from Previously Completed
Evidently the fda wanted to make sure that Dor's phase 3 trial survival advantage was not a fluke in a prospective analyis.
Since they are the one's that requested that dor analyse the phase 2 trial for the same endpoint it would lead me to believe this has a good chance to get approved.
they also put out important info regarding the make up of the patients. It is important to see that if anything the group on the drug were sicker.
Market Data 
Markets 
AI
